2:35 PM
 | 
May 31, 2018
 |  BC Extra  |  Clinical News

Clearside falls on Phase II DME data

Clearside Biomedical Inc. (NASDAQ:CLSD) lost $4.68 (32%) to $9.86 on Thursday after reporting that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular pressure and cataracts compared with Eylea alone in the Phase II TYBEE trial to treat diabetic macular edema.

The double-blind, U.S. trial enrolled 71 treatment-naïve patients to receive CLS-TA plus intravitreal Eylea at months zero and three, or four monthly treatments of Eylea. Patients in both arms could...

Read the full 393 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >